|Immunohistochemistry (IHC)||10-20 µg/ml|
|Western Blot (WB)||2 µg/ml|
|Tested Species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic peptide within the internal region of residues 200-300 of the human ATP13A2 protein.|
|Purification||Antigen affinity chromatography|
|Storage buffer||sodium borate|
|Storage conditions||4° C, store in dark|
Suggested positive control: human and mouse brain membrane prep lysate.
Neurodegenerative disorders such as Parkinson and Alzheimer disease cause motor and cognitive dysfunction and belong to a heterogeneous group of common and disabling disorders. ATP13A2, otherwise known as PARK9, is a neuronal P-type ATPase gene underlying an autosomal recessive form of early-onset parkinsonism with pyramidal degeneration and dementia. ATP13A2 protein is located in the membrane of these lysosomes and is formed most strongly in the brain, especially in the substantia nigra, a brain region which is known to play a central role in Parkinson's disease.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: ATPase type 13A2; Cation-transporting ATPase 13A2; HSA9947; KRPPD; PARK9; probable cation-transporting ATPase 13A2; putative ATPase; RP1-37C10.4
Gene Aliases: 1110012E06Rik; AA589443; ATP13A2; CLN12; HSA9947; KRPPD; PARK9
If an Invitrogen™ antibody doesn’t perform as described on our website or datasheet, we’ll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.